Clinical trials: sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder
This trial is a 52-week safety study to evaluate the safety of adjunctive aripiprazole in outpatients with major depressive disorder who have experienced an incomplete response to an ongoing antidepressant trial.
- Trial name
- NCT00095745
- Testing
- Antidepressant + Aripiprazole
- Where
- 58 sites in United States
- Volunteers
- 1,002 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia and Schizoaffective Disorder
A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices
The purpose of this clinical research study is to evaluate the overall effectiveness of 8 week of aripiprazole treatment.
- Trial name
- NCT00292409
- Testing
- Aripiprazole
- Volunteers
- 400 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices
The purpose of this clinical research study is to evaluate if Aripiprazole will prove to be effective, safe and well tolerated in the treatment of patients with schizophrenia who are treated in a general psychiatric setting.
- Trial name
- NCT00237939
- Testing
- Aripiprazole
- Where
- 20 sites in Belgium, France and 3 more
- Volunteers
- 1,200 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Parkinson's Disease, Psychoses
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
The purpose of this clinical research study is to assess the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.
- Trial name
- NCT00095810
- Testing
- aripiprazole
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Schizophrenia Trial of Aripiprazole
Aripiprazole will show improved effectiveness over the standard of care treatment with one of three atypical antipsychotics (olanzapine, quetiapine and risperidone).
- Trial name
- NCT00237913
- Testing
- Aripiprazole, Olanzapine or Quetiapine or Risperidone
- Where
- 33 sites in Austria, Czechia and 7 more
- Volunteers
- 700 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Healthy
Aripiprazole and Effexor XR Drug Interaction Study
The purpose of this clinical research study is to learn whether aripiprazole has effect on the steady-state pharmacokinetics of venlafaxine in healthy subjects.
- Trial name
- NCT00362271
- Testing
- Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Disorder, Major
Retrospective Database Study of Real World Abilify Outcomes in Major Depressive Disorder (MDD)
To examine the differences in health care utilization and costs between MDD patients on adjunctive aripiprazole therapy and MDD patients on other augmentation therapies.
- Trial name
- NCT01284218
- Volunteers
- 23,514 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder
Study of Aripiprazole in Patients With Acute Bipolar Mania
The purpose of this research study is to confirm the safety and effectiveness of aripiprazole therapy over 12 weeks in subjects with bipolar disorder experiencing symptoms of mania.
- Trial name
- NCT00097266
- Testing
- Aripiprazole, Haloperidol
- Where
- 45 sites in United States, Bulgaria and 5 more
- Volunteers
- 615 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Aripiprazole Oral Acceptability Trial
The purpose of this trial is to study liquid aripiprazole in patients with stable schizophrenia.
- Trial name
- NCT00101569
- Testing
- Aripiprazole
- Where
- 7 sites in United States
- Volunteers
- 59 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Effect on Cognitive Function of a Treatment With Aripiprazole
To evaluate the effectiveness of Aripiprazole after 12 weeks of therapy for Schizophrenic patients.
- Trial name
- NCT00329810
- Testing
- Aripiprazole
- Volunteers
- 500 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Healthy
Aripiprazole and Lexapro Drug Interaction Study
The purpose of this clinical research study is to learn whether aripiprazole has effect on the steady-state pharmacokinetics of escitalopram in healthy subjects.
- Trial name
- NCT00361790
- Testing
- Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7 days at 20 mg
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Disorder, Major
The Effect of Patient Cost-Sharing on Antidepressant and Adjunctive Therapy Use
The primary objective of this study is to measure the effects of patient cost-sharing on the initiation of adjunctive treatment and subsequent healthcare utilization and expenditures among a population of commercially insured…
- Trial name
- NCT01141400
- Volunteers
- 48,865 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Disorder, Major
Impact of Atypical Antipsychotic Therapy on Health Outcomes and Costs Among Patients With Major Depressive Disorder
The primary objective is to examine changes in pre/post-augmentation healthcare costs and resource utilization in patients diagnosed with major depressive disorder (MDD) who augment their current antidepressant therapy with an…
- Trial name
- NCT01145313
- Volunteers
- 501 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder
A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode
The purpose of this study is to evaluate flexible doses (5-30 mg) of aripiprazole in patients with bipolar depression.
- Trial name
- NCT00338273
- Testing
- Aripiprazole
- Where
- 8 sites in United States, India
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.
A Multicenter, Double-blind 16 Week Study on the augmentation of atypical antipsychotic with Aripiprazole in patients with Schizophrenia with inadequate response to antipsychotic treatment.
- Trial name
- NCT00325689
- Testing
- Quetiapine or Risperidone + Aripiprazole
- Where
- 48 sites in United States
- Volunteers
- 323 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Disorder, Major
Outcomes in MEasurement-Based Treatment
The primary objective for this study is to assess the impact of a measurement based treatment program (MBT) on Major Depressive Disorder (MDD) remission rates in patients whose primary care provider (PCP) receives monthly…
- Trial name
- COMET (NCT01141387)
- Volunteers
- 914 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder
Drug-drug Interaction Study of Aripiprazole and Lamotrigine in Patients With Bipolar Type I Disorder
The purpose of this clinical research study is to learn if aripiprazole has a drug-drug interaction with lamotrigine.
- Trial name
- NCT00321516
- Testing
- aripiprazole
- Where
- 4 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder
Study of Aripiprazole in Patients With Bipolar I Disorder
The purpose of this research study is to compare the efficacy of aripiprazole with placebo in combination with lithium or valproate monotherapy, in the treatment of bipolar I patients with manic or mixed episodes.
- Trial name
- NCT00257972
- Testing
- aripiprazole
- Where
- 90 sites in United States, Australia and 15 more
- Volunteers
- 400 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic Patients
The purpose of this study is to evaluate the effect on patient weight of adjunctive therapy of aripiprazole with clozapine versus clozapine monotherapy, in schizophrenic patients who are not optimally controlled on clozapine.
- Trial name
- NCT00300846
- Testing
- aripiprazole
- Where
- 57 sites in Austria, Czechia and 10 more
- Volunteers
- 200 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia
The purpose of this study is to compare the efficacy and tolerability of aripiprazole to olanzapine over 26 weeks for the treatment of schizophrenia
- Trial name
- NCT00712686
- Testing
- Aripiprazole, Olanzapine
- Volunteers
- 690 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.